DiscGenics is a biotechnology startup that operates in the medical sector, specifically focusing on the development of regenerative therapies for degenerative diseases of the spine. The company's mission is to improve the lives of patients suffering from chronic back pain, a condition that affects millions of people worldwide.

The company's primary product candidate is IDCT (rebonuputemcel), a non-surgical, injectable cell therapy. This therapy uses proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration. In simpler terms, the company is developing a treatment that can be injected into the spine to help repair damaged discs and alleviate back pain.

It's important to note that IDCT is still under development and has not yet been approved by the U.S. Food & Drug Administration (FDA) or any other regulatory agency for human use. This means that while the potential for this product is significant, there are still regulatory hurdles to overcome before it can be brought to market.

DiscGenics operates on a business model that involves the research, development, and eventual commercialization of its therapies. The company's revenue will primarily come from the sales of its products once they receive regulatory approval and are launched in the market.

The company's target market includes patients suffering from degenerative diseases of the spine, a group that represents a significant portion of the population. With an aging global population, the demand for effective treatments for conditions like chronic back pain is expected to grow, presenting a potentially lucrative market for DiscGenics' therapies.

Keywords: Biotechnology, Medical Sector, Regenerative Therapies, Degenerative Spinal Diseases, Chronic Back Pain, IDCT (rebonuputemcel), Non-Surgical Treatment, Discogenic Cells, Research and Development, Regulatory Approval.